What are thymic neuroendocrine tumours?
Thymic neuroendocrine tumours (thymic NETs) are rare cancers of the thymus that grow from neuroendocrine cells. These are cells that behave partly like nerve cells and partly like hormone-producing gland cells. The thymus is a small organ in the front of the chest, behind the breastbone, which helps the immune system develop in early life.
The best-known thymic NETs are thymic carcinoids, which are divided into typical and atypical carcinoids. The group also includes two high-grade cancers, large cell neuroendocrine carcinoma and small cell carcinoma of the thymus. Thymic NETs make up only about 2-5% of all thymic tumours (Lausi et al., 2014).
Despite the gentle-sounding name, thymic carcinoids tend to behave more aggressively than carcinoids in other parts of the body, such as the lung or bowel (Lausi et al., 2014). They are more common in men, usually in middle age, and some are linked with an inherited condition called multiple endocrine neoplasia type 1 (MEN1).
The main treatment is surgery to remove the tumour completely. Radiotherapy, drug treatments and newer targeted therapies are used for tumours that cannot be fully removed or that have spread.
How thymic NETs differ from thymoma and thymic carcinoma
Thymic NETs are a different disease from the more common thymic tumours, thymoma and thymic carcinoma, which grow from the thymus’s epithelial cells. We describe those tumours in a separate article: Thymoma and thymic carcinoma.
| Feature | Thymic neuroendocrine tumours | Thymoma and thymic carcinoma |
|---|---|---|
| Cell of origin | Neuroendocrine cells | Thymic epithelial cells |
| How common | About 2-5% of thymic tumours | The large majority of thymic tumours |
| Hormone production | Can make hormones such as ACTH, causing Cushing’s syndrome | Not typical |
| Linked immune conditions | Not typical | Thymoma often linked with myasthenia gravis |
| Inherited link | MEN1 syndrome in some patients | Rare |
| Key microscope features | Neuroendocrine markers such as synaptophysin and chromogranin | Epithelial and lymphocyte-rich patterns |
| Grading | Typical carcinoid, atypical carcinoid, large cell and small cell carcinoma | WHO thymoma types A, AB, B1-B3; thymic carcinoma |
| Special scans | Somatostatin receptor PET often helpful | Not usually used |
| Drug options | Somatostatin analogues, everolimus, PRRT, chemotherapy | Chemotherapy, some targeted drugs |
The two groups occur in the same location and can look alike on a CT scan, so the difference is confirmed by the pathologist.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Neuroendocrine neoplasm of the thymus |
| Where it grows | Anterior mediastinum, behind the breastbone |
| How common | Rare; 2-5% of thymic tumours |
| Who is affected | Mainly men; median age in the 50s |
| Inherited link | MEN1 syndrome in a minority |
| Hormone syndromes | Cushing’s syndrome from ACTH in some patients |
| Main treatment | Complete surgical removal |
| Other treatments | Radiotherapy, somatostatin analogues, everolimus, PRRT, chemotherapy |
| Outlook | About 62% alive at 5 years in a national database |
2. Types
| Type | Grade | Features | Behaviour |
|---|---|---|---|
| Typical carcinoid | Low | Few dividing cells, no necrosis | Slowest growing, but can still spread |
| Atypical carcinoid | Intermediate | More dividing cells and/or focal necrosis | Frequently spreads |
| Large cell neuroendocrine carcinoma | High | Large cells, many mitoses, extensive necrosis | Aggressive |
| Small cell carcinoma | High | Small cells, very high proliferation | Aggressive; behaves like small cell lung cancer |
Thymic carcinoids compared with carcinoids elsewhere
| Feature | Thymic carcinoid | Lung or bowel carcinoid |
|---|---|---|
| Typical stage at diagnosis | Often locally advanced | Often localised |
| Carcinoid syndrome (flushing, diarrhoea) | Rare | More common with liver spread from bowel tumours |
| Cushing’s syndrome | Relatively frequent | Less frequent |
| Recurrence | Common, sometimes years later | Less common for typical carcinoids |
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Male sex | Thymic NETs mainly affect men (Gaur, Leary and Yao, 2010) |
| Middle age | Median age 57 in a national database |
| MEN1 syndrome | Inherited condition causing parathyroid, pancreatic and pituitary tumours; thymic carcinoids occur in some, usually men |
For most patients, the cause is unknown.
Thymic carcinoid and MEN1
People with MEN1 often have operations on their parathyroid glands. Guidelines have advised removing the thymus at the same time to prevent thymic carcinoid. A review of 122 patients found that this rarely detected a tumour, and some patients still developed a thymic carcinoid later. The authors concluded that careful long-term imaging surveillance may be more important (De Jong and Parameswaran, 2022).
4. How does it look
On scans
| Test | Typical findings |
|---|---|
| Chest X-ray | Widened shadow in the middle of the chest |
| CT scan | Mass in the anterior mediastinum, often large and sometimes invading nearby structures |
| MRI | Helps assess invasion of vessels and heart lining |
| Somatostatin receptor PET (for example Ga-68 DOTATATE) | Shows receptor-positive tumour and spread |
| FDG PET-CT | More useful for higher-grade tumours |
Under the microscope
| Feature | Description |
|---|---|
| Pattern | Nests, ribbons and rosettes of uniform cells |
| Neuroendocrine markers | Synaptophysin, chromogranin A, INSM1 positive |
| Mitotic count and necrosis | Separate typical from atypical carcinoid |
| Ki-67 index | Indicates growth rate |
| Hormone stains | ACTH staining in tumours causing Cushing’s syndrome |
5. Symptoms
Some patients have no symptoms, and the tumour is found on a chest scan done for another reason.
Common symptoms
- Chest pain or pressure
- Cough
- Shortness of breath
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Weight gain in the face and trunk, thin skin, high blood pressure, high blood sugar, muscle weakness | Cushing’s syndrome from ACTH production |
| Swelling of the face, neck and arms | Pressure on the superior vena cava |
| Hoarse voice | Pressure on the nerve to the voice box |
| Bone pain | Spread to bone |
| Flushing and diarrhoea | Carcinoid syndrome (rare) |
| Kidney stones, bone thinning | High calcium from parathyroid disease in MEN1 |
When to seek medical advice
See a doctor for persistent chest pain, cough or breathlessness, or for features of Cushing’s syndrome such as rapid weight gain, purple stretch marks and easy bruising. People with MEN1 should attend their planned surveillance scans.
6. Diagnosis
| Test | Purpose |
|---|---|
| CT of the chest | Size and extent of the tumour |
| Somatostatin receptor PET-CT | Staging and checking receptor status for treatment |
| Biopsy | CT-guided needle or surgical biopsy, when the diagnosis is uncertain |
| Blood tests: chromogranin A, cortisol, ACTH | Detect hormone production |
| Calcium, parathyroid hormone, pituitary tests | Screen for MEN1 |
| Genetic testing for MEN1 | Especially in younger patients or with a family history |
| Lung function tests | Before surgery |
Staging
There is no staging system designed specifically for thymic NETs. Doctors use the TNM system for thymic tumours or the Masaoka-Koga system. A specific staging system has been called for (Gaur, Leary and Yao, 2010).
| Stage group | General meaning |
|---|---|
| Localised | Confined to the thymus and its capsule |
| Locally advanced | Invades nearby fat, pleura, pericardium, lung or vessels |
| Nodal spread | Involves chest lymph nodes |
| Distant spread | Bone, liver, lung or other organs |
7. Treatment
Treatment is planned by a multidisciplinary team with experience in thoracic surgery and neuroendocrine tumours. European guidance on lung and thymic carcinoids provides practical recommendations for diagnosis, treatment and follow-up (Baudin et al., 2026).
Surgery
| Aspect | Details |
|---|---|
| Aim | Complete removal of the tumour and the whole thymus |
| Approach | Usually through the breastbone (sternotomy); minimally invasive surgery for small tumours |
| Extended resection | Parts of the lung, pericardium or vessels may be removed |
| Lymph nodes | Sampling or removal is recommended |
| Effect on survival | Surgery is linked with better survival in database studies |
In SEER data, surgery was associated with better survival, while radiotherapy as part of primary treatment showed no clear benefit (Gaur, Leary and Yao, 2010).
Radiotherapy
| Situation | Role |
|---|---|
| Positive margins | Linked with improved survival in national data (Bakhos et al., 2020) |
| Locally advanced tumours | Considered after surgery |
| Tumours that cannot be removed | Combined with drug treatment |
| Painful bone spread | Symptom relief |
Drug treatments for advanced disease
| Treatment | Notes |
|---|---|
| Somatostatin analogues (octreotide, lanreotide) | Slow growth of receptor-positive tumours; control hormone symptoms |
| Everolimus | Targeted tablet for progressive carcinoids |
| Peptide receptor radionuclide therapy (PRRT) | Radioactive treatment for receptor-positive tumours |
| Chemotherapy | Temozolomide-based or platinum-etoposide regimens, especially for higher grades |
| Clinical trials | Encouraged for advanced disease (Lausi et al., 2014) |
Treating Cushing’s syndrome
| Treatment | Purpose |
|---|---|
| Removing the tumour | The most effective way to cure the hormone excess |
| Cortisol-lowering medicines | Control symptoms before surgery or if the tumour cannot be removed |
| Adrenal gland removal | A last resort for uncontrolled Cushing’s syndrome |
Recovery after thymic surgery
| Period | What to expect |
|---|---|
| Hospital stay | Usually 3-7 days after sternotomy; shorter after keyhole surgery |
| First 6 weeks | Breastbone healing; avoid heavy lifting and driving |
| 6-12 weeks | Gradual return to normal activities and work |
| Longer term | Breathing and fitness continue to improve with exercise |
Side effects
| Treatment | Possible side effects |
|---|---|
| Sternotomy | Chest pain, slow bone healing, breathing problems, infection |
| Radiotherapy | Tiredness, sore swallowing, lung or heart inflammation |
| Somatostatin analogues | Loose stools, abdominal discomfort, gallstones |
| Everolimus | Mouth ulcers, rash, lung inflammation, high blood sugar |
| PRRT | Nausea, low blood counts, kidney effects |
| Chemotherapy | Tiredness, infection risk, nausea |
8. Outlook (prognosis)
| Factor | Effect |
|---|---|
| Stage | Advanced stage is linked with poorer survival |
| Grade | Higher grade is linked with poorer survival |
| Tumour size | Larger tumours do worse |
| Complete surgical removal | Better survival |
| Age and other illnesses | Affect survival |
In a national database of nearly 1,500 patients with thymic NETs or thymic carcinoma, five-year survival was 62% for thymic NETs (Bakhos et al., 2020). Stage, grade, surgical removal and tumour size were all linked with survival in SEER data (Gaur, Leary and Yao, 2010).
Recurrence is common and can occur many years after surgery, so long-term follow-up is needed.
9. Follow-up
| Time | Typical checks |
|---|---|
| First 2 years | CT every 6 months |
| Years 3-5 | CT every 6-12 months |
| After 5 years | Yearly imaging, often for 10 years or longer |
| Somatostatin receptor PET | If recurrence is suspected |
| Hormone tests | If Cushing’s syndrome was present |
| MEN1 surveillance | Lifelong, for patients with MEN1 |
10. Living with a thymic neuroendocrine tumour
- Keep follow-up scans, even many years after treatment
- Tell relatives about MEN1 if you have it, so they can be offered testing
- Stop smoking to protect your lungs and heart, especially after chest surgery
- Report new symptoms, such as chest pain, weight change or bone pain
- Rebuild fitness gradually after chest surgery, with physiotherapy if offered
- Seek support from neuroendocrine tumour charities and patient groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is a thymic carcinoid the same as thymoma? | No; it comes from different cells and is treated differently |
| Is it benign because it is called a carcinoid? | No; thymic carcinoids are cancers and can spread |
| Why test for MEN1? | Some thymic carcinoids are part of this inherited condition |
| Can it cause hormone problems? | Yes, most often Cushing’s syndrome |
| Will I need chemotherapy? | Not usually after complete removal; it is used for advanced or high-grade disease |
| Can it come back? | Yes, sometimes years later |
| Is it inherited? | Usually not, but a minority of patients have MEN1, which can run in families |
| Can I return to work? | Most people can, typically a few months after surgery |
| What is a somatostatin receptor scan? | A PET scan using a tracer that sticks to receptors on many NET cells |
12. Questions to ask your care team
- Is my tumour a typical or atypical carcinoid, or a high-grade carcinoma?
- Should I be tested for MEN1?
- Is the tumour producing hormones?
- Can it be completely removed?
- Will I need radiotherapy or drug treatment?
- Does my tumour show up on a somatostatin receptor scan?
- How long will follow-up continue?
Resources
- Bakhos, C.T. et al. (2020) ‘Thymic neuroendocrine tumors and thymic carcinoma: demographics, treatment, and survival’, Innovations (Philadelphia), 15(5), pp. 468-474.
- Baudin, E. et al. (2026) ‘European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids’, Journal of Neuroendocrinology, 38(4), e70174.
- De Jong, M.C. and Parameswaran, R. (2022) ‘Revisiting the evidence for routine transcervical thymectomy for the prevention of thymic carcinoid tumours in MEN-1 patients’, Oncology, 100(12), pp. 696-700.
- Gaur, P., Leary, C. and Yao, J.C. (2010) ‘Thymic neuroendocrine tumors: a SEER database analysis of 160 patients’, Annals of Surgery, 251(6), pp. 1117-1121.
- Lausi, P.O. et al. (2014) ‘Thymic neuroendocrine tumors’, Thoracic Surgery Clinics, 24(3), pp. 327-332.
- National Cancer Institute (2026) Thymoma and Thymic Carcinoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/thymus-cancer/hp/thymoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.